SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Nanobiotix S.A. (NBTX) News

Follow Nanobiotix S.A. (NBTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol NBTX Asset equity Sector Markets 90 days 5 Last 26.55 Updated Oct 26, 2026, 08:38 AM UTC Open live news feed Open NBTX chart & news
M Nanobiotix Reports 41.7% Response Rate for JNJ-1900 Melanoma Study Nanobiotix reported a 41.7% response rate for JNJ-1900 in a Phase I study of anti-PD-1-resistant melanoma. EQUITY | Oct 26, 2026, 08:38 AM UTC L NBTX - Voting Rights and Shares Capital of the Company NBTX - Voting Rights and Shares Capital of the Company EQUITY | Sep 22, 2026, 08:15 PM UTC L NBTX - NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer NBTX - NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer NEWS | Sep 14, 2026, 06:00 AM UTC L NBTX - NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference NBTX - NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference EQUITY | Sep 09, 2026, 08:15 PM UTC L NBTX - Voting Rights and Shares Capital of the Company NBTX - Voting Rights and Shares Capital of the Company EQUITY | Aug 25, 2026, 08:15 PM UTC